Lacosamide Injection
Product Images NDC 69367-352

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lacosamide (NDC 69367-352). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Westminster Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Lacosamide 01)

Chemical structure of lacosamide, depicting its molecular arrangement including functional groups such as an amide and a benzyl group, consistent with the active ingredient lacosamide used in the injection dosage form.*

FDA Label Image

Figure 1 (Lacosamide 02)

A bar chart showing median percent seizure reduction from baseline for Lacosamide injection at various dosages compared to placebo across three clinical studies. The chart displays seizure reduction percentages for placebo and Lacosamide doses ranging from 200 to 600 mg/day, highlighting statistically significant improvements with Lacosamide over placebo.*

FDA Label Image

Figure 2 (Lacosamide 03)

A responder rate curve chart showing responder rate (equal to or greater improvement vs worsening) on the vertical axis, plotted against percent of patients on the horizontal axis. The chart compares Placebo and Lacosamide at 200 mg/day, 400 mg/day, and 600 mg/day doses, with four distinct lines representing each group.*

FDA Label Image

Figure 3 (Lacosamide 04)

A Kaplan-Meier survival curve comparing the proportion of patients over time (days) between Lacosamide injection (10 mg/mL) and placebo groups. The graph shows higher survival proportions for Lacosamide patients compared to placebo, with survival probabilities plotted along the y-axis and time in days along the x-axis. A table below the x-axis displays the number of patients at risk over time for both groups.*

FDA Label Image

Principal Display Panel (20 mL Vial Carton)

Packaging label for Lacosamide Injection, USP 10 mg/mL (200 mg/20 mL) intravenous injection by Westminster Pharmaceuticals, LLC. The carton is designed for 10 single-dose 20 mL vials. The label includes directions for pharmacists to dispense a separate Medication Guide and storage instructions, and lists inactive ingredients and manufacturer information for OP NanoPharma Co., Ltd., Taiwan.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.